Escherichia Coli Infections - Pipeline Review, H2 2015 - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/tb4wt7/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Escherichia Coli Infections Overview
  3. Therapeutics Development
  4. Pipeline Products for Escherichia Coli Infections - Overview
  5. Pipeline Products for Escherichia Coli Infections - Comparative Analysis
  6. Escherichia Coli Infections - Therapeutics under Development by Companies
  7. Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes
  8. Escherichia Coli Infections - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Escherichia Coli Infections - Products under Development by Companies
  13. Escherichia Coli Infections - Products under Investigation by Universities/Institutes
  14. Escherichia Coli Infections - Companies Involved in Therapeutics Development
  • Adenium Biotech ApS
  • Arsanis Biosciences GmbH
  • AstraZeneca Plc
  • AvidBiotics Corp.
  • Bioorganic Research and Services S.A.
  • Cellceutix Corporation
  • Chiesi Farmaceutici SpA
  • Debiopharm International S.A.
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • GangaGen Inc.
  • GlaxoSmithKline Plc
  • Immuron Limited
  • Melinta Therapeutics, Inc
  • Microbiotix, Inc.
  • MicuRx Pharmaceuticals, Inc.
  • Mucosis B.V.
  • Navigen Pharmaceuticals, Inc.
  • Nosopharm SAS
  • Novabiotics Limited
  • Nymox Pharmaceutical Corporation
  • Pherecydes Pharma SA
  • Phico Therapeutics Limited
  • Procarta Biosystems Ltd
  • Sanofi Pasteur SA
  • Sealife PHARMA GMBH
  • Sequoia Sciences, Inc.
  • Soligenix, Inc.
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc.
  • Trana Discovery, Inc.
  • Varinel, Inc.

For more information visit http://www.researchandmarkets.com/research/tb4wt7/escherichia_coli

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases